Neurocrine Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Neurocrine Biosciences
NBIX Stock  USD 110.31  0.61  0.56%   
Neurocrine Biosciences financial statements provide useful quarterly and yearly information to potential Neurocrine Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Neurocrine Biosciences financial statements helps investors assess Neurocrine Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Neurocrine Biosciences' valuation are summarized below:
Gross Profit
1.6 B
Profit Margin
0.1449
Market Capitalization
10.9 B
Enterprise Value Revenue
4.3801
Revenue
2.4 B
We have found one hundred twenty available fundamental ratios for Neurocrine Biosciences, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Neurocrine Biosciences last-minute market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 6.5 B in 2025. Enterprise Value is likely to rise to about 6.6 B in 2025

Neurocrine Biosciences Total Revenue

2.47 Billion

Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.5 M, Interest Expense of 7.4 M or Selling General Administrative of 1.1 B, as well as many indicators such as Price To Sales Ratio of 5.53, Dividend Yield of 0.0 or PTB Ratio of 6.06. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
  
Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Neurocrine Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.9 B3.7 B1.4 B
Slightly volatile
Short and Long Term Debt Total477.9 M455.1 M412.7 M
Slightly volatile
Other Current Liabilities417.6 M397.7 M124.4 M
Slightly volatile
Total Current Liabilities533.1 M507.7 M220.2 M
Slightly volatile
Total Stockholder Equity2.7 B2.6 B912.1 M
Slightly volatile
Property Plant And Equipment Net621.6 M592 M135.7 M
Slightly volatile
Accounts Payable115.5 M110 M35.6 M
Slightly volatile
Cash136.2 M233 M180.8 M
Slightly volatile
Non Current Assets Total2.1 B2 B604.6 M
Slightly volatile
Non Currrent Assets Other792.8 M755 M104.7 M
Slightly volatile
Cash And Short Term Investments1.1 B1.1 B557.3 M
Slightly volatile
Net Receivables503.1 M479.1 M152.4 M
Slightly volatile
Common Stock Shares Outstanding63.6 M103.7 M80.9 M
Slightly volatile
Liabilities And Stockholders Equity3.9 B3.7 B1.4 B
Slightly volatile
Non Current Liabilities Total652.4 M621.3 M231.2 M
Slightly volatile
Other Current Assets117.7 M112.1 M53.8 M
Slightly volatile
Other Stockholder Equity2.7 B2.6 B1.6 B
Slightly volatile
Total Liabilities1.2 B1.1 B451.4 M
Slightly volatile
Property Plant And Equipment Gross733.4 M698.5 M154.6 M
Slightly volatile
Total Current Assets1.8 B1.7 B759 M
Slightly volatile
Short Term Debt205.4 M195.6 M84.4 M
Slightly volatile
Short Term Investments885.3 M843.1 M412.4 M
Slightly volatile
Other Liabilities24.8 M34.2 M22.7 M
Pretty Stable
Other Assets399.6 M380.5 M158.4 M
Slightly volatile
Common Stock Total Equity67.8 K115 K82.3 K
Slightly volatile
Common Stock71.2 K115 K82.5 K
Slightly volatile
Property Plant Equipment55.4 M52.7 M27.7 M
Slightly volatile
Net Tangible Assets2 B1.9 B768.3 M
Slightly volatile
Capital Surpluse1.6 B2.4 B1.5 B
Slightly volatile
Non Current Liabilities Other5.2 M5.5 M28.1 M
Slightly volatile
Long Term Investments907.5 M864.3 M298.5 M
Slightly volatile
Long Term Debt Total291.2 M301.6 M354.4 M
Slightly volatile
Net Invested Capital1.5 B2.6 B1.1 B
Slightly volatile
Short and Long Term Debt193 M153.1 M279.9 M
Slightly volatile
Net Working Capital832.9 M1.2 B649.6 M
Slightly volatile
Capital Stock107.3 K115 K95.8 K
Slightly volatile
Capital Lease Obligations477.9 M455.1 M147 M
Slightly volatile

Neurocrine Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization28.5 M27.1 M8.3 M
Slightly volatile
Selling General Administrative1.1 B1 B351.3 M
Slightly volatile
Other Operating Expenses1.9 B1.8 B622 M
Slightly volatile
Research Development767.7 M731.1 M247.2 M
Slightly volatile
Total Operating Expenses1.8 B1.8 B611.4 M
Slightly volatile
Selling And Marketing Expenses65.6 K73.8 K80.5 K
Slightly volatile
Interest Income95.5 M91 M20 M
Slightly volatile
Reconciled Depreciation28.5 M27.1 M8.8 M
Slightly volatile
Non Recurring113.1 M94.8 M139.4 M
Slightly volatile

Neurocrine Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow272.1 M259.1 M141.6 M
Slightly volatile
Capital Expenditures40.1 M38.2 M13.5 M
Slightly volatile
End Period Cash Flow253.1 M241 M152.1 M
Slightly volatile
Stock Based Compensation205.3 M195.5 M78.9 M
Slightly volatile
Issuance Of Capital Stock22.9 M26 M28.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.535.818665.9461
Slightly volatile
PTB Ratio6.065.2928.3572
Very volatile
Days Sales Outstanding39.5574.24657.36
Slightly volatile
Book Value Per Share27.0825.79389.8689
Slightly volatile
Stock Based Compensation To Revenue0.07890.0830.5247
Slightly volatile
PB Ratio6.065.2928.3572
Very volatile
EV To Sales5.625.912964.1326
Slightly volatile
Sales General And Administrative To Revenue0.470.51.146
Pretty Stable
Research And Ddevelopement To Revenue0.290.31042.0537
Slightly volatile
Capex To Revenue0.01540.01620.0608
Slightly volatile
Cash Per Share11.2510.71816.5073
Slightly volatile
Intangibles To Total Assets0.00930.00980.0221
Slightly volatile
Current Ratio3.233.39717.7624
Slightly volatile
Tangible Book Value Per Share26.725.43039.7488
Slightly volatile
Receivables Turnover4.674.916115.7535
Slightly volatile
Graham Number46.6444.417115.9646
Slightly volatile
Shareholders Equity Per Share27.0825.79389.8689
Slightly volatile
Debt To Equity0.290.17570.6287
Slightly volatile
Capex Per Share0.240.38050.1363
Slightly volatile
Graham Net Net3.63.33792.9347
Slightly volatile
Revenue Per Share24.6323.45927.8435
Slightly volatile
Interest Debt Per Share4.764.53294.2166
Slightly volatile
Debt To Assets0.10.12240.3044
Slightly volatile
Short Term Coverage Ratios2.772.641.5897
Very volatile
Price Book Value Ratio6.065.2928.3572
Very volatile
Ebt Per Ebit1.50.85191.1077
Slightly volatile
Company Equity Multiplier1.821.4361.552
Pretty Stable
Long Term Debt To Capitalization0.140.130.3219
Slightly volatile
Total Debt To Capitalization0.140.14950.343
Slightly volatile
Debt Equity Ratio0.290.17570.6287
Slightly volatile
Quick Ratio3.123.2847.8062
Slightly volatile
Net Income Per E B T0.850.70231.0764
Very volatile
Cash Ratio0.440.45892.079
Slightly volatile
Days Of Sales Outstanding39.5574.24657.36
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.93581.0156
Slightly volatile
Price To Book Ratio6.065.2928.3572
Very volatile
Fixed Asset Turnover5.793.978510.862
Slightly volatile
Debt Ratio0.10.12240.3044
Slightly volatile
Price Sales Ratio5.535.818665.9461
Slightly volatile
Asset Turnover0.670.63340.3836
Slightly volatile
Price Fair Value6.065.2928.3572
Very volatile

Neurocrine Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap6.5 B6.1 B4.6 B
Slightly volatile
Enterprise Value6.6 B6.2 B4.6 B
Slightly volatile

Neurocrine Fundamental Market Drivers

Forward Price Earnings22.0751
Cash And Short Term Investments1.1 B

Neurocrine Upcoming Events

7th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue263.7 M276.9 M
Total Revenue2.4 B2.5 B
Cost Of Revenue34 M38.5 M
Stock Based Compensation To Revenue 0.08  0.08 
Sales General And Administrative To Revenue 0.50  0.47 
Research And Ddevelopement To Revenue 0.31  0.29 
Capex To Revenue 0.02  0.02 
Revenue Per Share 23.46  24.63 
Ebit Per Revenue 0.24  0.25 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY